Literature DB >> 15642902

HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.

K Geleijns1, G M Th Schreuder, B C Jacobs, K Sintnicolaas, R van Koningsveld, J Meulstee, J D Laman, P A van Doorn.   

Abstract

OBJECTIVE: To assess whether human leukocyte antigen (HLA)-DRB1 and HLA-DQB1 alleles confer susceptibility to Guillain-Barre syndrome (GBS) or are related to specific clinical or serologic subgroups of GBS.
METHODS: The HLA-DRB1 and HLA-DQB1 loci were genotyped by PCR amplification with sequence-specific primers in 164 well-documented Dutch patients with GBS and 207 healthy Dutch control subjects. Patients with GBS were divided into subgroups based on clinical features, severity of disease, antecedent infection, and anti-ganglioside antibodies. Data were compared with those of all case-control HLA studies in GBS performed previously.
RESULTS: In this case-control study, HLA-DRB1 and HLA-DQB1 alleles did not differ between GBS patients and control subjects. The frequency of HLA-DRB1*01 was increased in patients who needed mechanical ventilation (odds ratio 4.2; 95% CI 1.9 to 9.6; p(c) = 0.02). Multivariate logistic regression analysis showed that this association was independent of the severity of paresis and the presence of cranial nerve involvement (all p < 0.05). There was a tendency toward an association between certain HLA alleles and several anti-ganglioside antibodies.
CONCLUSIONS: Human leukocyte antigen (HLA) class II antigens are not a general susceptibility factor in Guillain-Barre syndrome (GBS). However, HLA class II alleles may be a determinant in distinct subgroups of GBS, indicating the need for further exploration in large-scale studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642902     DOI: 10.1212/01.WNL.0000148727.02732.01

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 2.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

3.  Sulfoglucuronosyl paragloboside promotes endothelial cell apoptosis in inflammation: elucidation of a novel glycosphingolipid-signaling pathway.

Authors:  Somsankar Dasgupta; Guanghu Wang; Robert K Yu
Journal:  J Neurochem       Date:  2011-10-11       Impact factor: 5.372

4.  Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Daniel Gaudet; Diane Brisson; Lisa Christopher-Stine; Thomas E Lloyd; Mary S Leffell; Andrea A Zachary
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

5.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

Review 6.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

Review 7.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 8.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.

Authors:  S Usuki; K Taguchi; S A Thompson; P B Chapman; R K Yu
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 10.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.